05:07:52 EST Wed 11 Nov 2026
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Q:VKTX - VIKING THERAPEUTICS INC - https://www.vikingtherapeutics.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VKTX - Q1.028.65·28.752.028.66-0.33-1.14,260.2121,98926,71928.95  30.10  28.390143.15  23.82Nov 10Nov 0915 min RT 2¢

Recent Trades - Last 10 of 26719
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-11-09 07:05U:VKTXNews ReleaseViking Therapeutics Announces Two Poster Presentations at ObesityWeek(TM) 2026
2026-11-03 16:30U:VKTXNews ReleaseViking Therapeutics to Participate at Upcoming Investor Conferences
2026-11-03 09:00U:VKTXNews ReleasePeptide Therapies Are Changing the Future of Medicine - And the Market Could Reach $335 Billion
2026-10-28 16:05U:VKTXNews ReleaseViking Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-10-21 16:05U:VKTXNews ReleaseViking Therapeutics to Report Financial Results for Third Quarter 2026 on October 28, 2026
2026-10-14 07:05U:VKTXNews ReleaseViking Therapeutics Announces Initiation of VK2735 Oral Phase 3 Clinical Program in Patients with Obesity
2026-10-06 07:05U:VKTXNews ReleaseViking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial in Patients with Obesity
2026-09-28 16:30U:VKTXNews ReleaseViking Therapeutics Announces Closing of Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes, Including Full Exercise of Underwriters' Options to Purchase Additional Shares of Common Stock and Convertible Senior Notes
2026-09-24 07:05U:VKTXNews ReleaseViking Therapeutics Prices Upsized $500 Million Offering of Common Stock and Convertible Senior Notes
2026-09-23 16:32U:VKTXNews ReleaseViking Therapeutics Announces Proposed Offerings of Common Stock and Convertible Senior Notes
2026-09-22 07:05U:VKTXNews ReleaseViking Therapeutics Announces Positive Topline Results from Maintenance Study of GLP-1/GIP Agonist VK2735 Demonstrating the Promise of Multiple Maintenance Dosing Regimens
2026-09-02 16:05U:VKTXNews ReleaseViking Therapeutics to Participate at Upcoming Investor Conferences
2026-07-29 16:05U:VKTXNews ReleaseViking Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-07-23 07:05U:VKTXNews ReleaseViking Therapeutics Appoints Dorothy Gemmell to Board of Directors
2026-07-22 16:05U:VKTXNews ReleaseViking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026
2026-06-24 07:05U:VKTXNews ReleaseViking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
2026-06-11 07:05U:VKTXNews ReleaseViking Therapeutics Announces Appointment of Hubert C. Chen, M.D., as Chief Medical Officer
2026-05-21 07:05U:VKTXNews ReleaseViking Therapeutics to Participate at Upcoming Investor Conferences
2026-05-13 08:30U:VKTXNews ReleaseNext-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities
2026-05-12 07:05U:VKTXNews ReleaseViking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026